jeudi 22 novembre 2018

Onco Actu du 22 novembre 2018

1. Biologie

Sugar supplement slows cancer growth in mice, but patients shouldn’t rush to health food shops [Cancer Research UK]

1.4 Biologie - Technos

‘A new instruction manual for life’: Single-cell sequencing is opening up new avenues for potential treatments [STAT]

2.7 Etiologie - Obésité

Teen obesity tied to increased risk of pancreatic cancer [Reuters]

3.1.1 Prévention - Tabac - e-cigs

Vaping no boost to quit rates in smokers, study suggests [Ohio Sate University]

4.12 Biopsies liquides

Liquid Biopsy Shows Promise in Prostate Cancer Across Multiple Biomarkers [Genome Web]

4.9 Dép., diag. & prono. - Sein

Risk stratification in breast screening: A word of caution [Journal of Medical Screening]

5.1 Traitements - Pré-clinique

Tumour microenvironment the new battlespace in the war against cancer [Cancer World]

5.12.8 Immunothérapies - Economie

Immunotherapy drug to be made available for some NHS patients with advanced skin cancer [Cancer Research UK]

5.2.3 Pharma - économie

Former Aveo CFO found guilty of misleading investors about prospects for cancer drug [FiercePharma]

5.3 Traitements - FDA, EMA, NICE...

Towards electronic product information for EU medicines [EMA]

5.3.4 Traitements - AMM (FDA, EMA,...)

Roche announces FDA grants Venclexta accelerated approval for people with newly-diagnosed acute myeloid leukaemia or those who are ineligible for intensive induction chemotherapy [Roche]

U.S. FDA Approves DAURISMO™ (glasdegib) for Adult Patients with Newly-Diagnosed Acute Myeloid Leukemia (AML) for Whom Intensive Chemotherapy is Not an Option [Pfizer]

FDA Approvals Provide Advances in Precision Medicine and Immunotherapy [Cancer Research Catalyst]

Playing a hot hand in cancer R&D, Pfizer scores its 4th drug approval in just 2 months [EndPoints]

FDA approves new blood cancer treatment from Pfizer [Reuters]

FDA approves new treatment for patients with acute myeloid leukemia [FDA]

6.6 Publications

To catch misconduct, journals are hiring research integrity czars [STAT]